FDA Inspection 1300792 — Piedmont Reproductive Endocrinology Group, Pa
The FDA completed an inspection of Piedmont Reproductive Endocrinology Group, Pa on Jan 21, 2026 in Greenville, SC. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). 1 citation was issued during this inspection. Product area: Biologics.
Inspection details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Jan 21, 2026
- Fiscal Year
- 2026
- Product Type
- Biologics
- Project Area
- Human Cellular, Tissue, and Gene Therapies
- Location
- Greenville, SC (United States)
Citations
| ID | CFR | Description |
|---|---|---|
| 12283 | 21 CFR 1271.75(e) | Abbreviated procedure |